A novel non-invasive and non-ionizing medical device for monitoring patients wit...
A novel non-invasive and non-ionizing medical device for monitoring patients with implanted stents
Susana Amorós is the CTO and co-founder of NIMBLE Diagnostics, a MedTech company developing a first in class microwave-based medical device for the continuos, non-invasive, non-ionizing monitoring of patients with implanted stents...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
NIMBLE System
"The NIMBLE System: A novel non-invasive and non-ionizing me...
3M€
Cerrado
TEC2013-49465-EXP
DETECCION DE DEFECTOS ESTRUCTURALES POR DETERIORO DE STENTS...
92K€
Cerrado
PCIN-2013-068
CATETERES INTELIGENTES EN SISTEMAS AVANZADOS PARA INTERVENCI...
25K€
Cerrado
BES-2010-032893
INSTRUMENTACION NO INVASIVA PARA MONITORIZAR Y EVALUAR TENDE...
43K€
Cerrado
StentGuard
Clinical validation of the First Implantable Sensor System f...
11M€
Cerrado
CPP2021-008562
CARE-ECGI - Terapia de resincronización cardiaca basada en i...
708K€
Cerrado
Información proyecto NIMBLE WOMENTECHEU
Duración del proyecto: 12 meses
Fecha Inicio: 2023-05-26
Fecha Fin: 2024-05-31
Líder del proyecto
NIMBLE DIAGNOSTICS
Fabricación de equipos de radiación, electromédicos y electroterapéuticos sociedad limitada
TRL
8-9
Presupuesto del proyecto
75K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Susana Amorós is the CTO and co-founder of NIMBLE Diagnostics, a MedTech company developing a first in class microwave-based medical device for the continuos, non-invasive, non-ionizing monitoring of patients with implanted stents.
Stents are one of the most implanted devices worldwide and are used to restore the correct flow of blood or other fluids. They are especially useful to prevent heart attacks or to treat their lasting symptoms, but once implanted can become blocked or damaged, which occur in 30% of the cases. The symptoms only appear after a stent is already 90% dysfunctional, which increases the incidence
of serious complications, including strokes, heart attacks or sudden death. The standard-of-care is still symptom-driven and is based on an invasive procedure called catheter angiography, involving anesthesia, X-ray exposure and 24h hospitalization recovery. This complex procedure is not standardized for recurrent monitoring, not allowing clinicians to act upon the problem until it has already manifested.
The NIMBLE System can read the electromagnetic signature of the stent non-invasively, providing information on stent satus and malfunction that can be correlated with relevant clinical outcomes. Thus, NIMBLE enables early treatments to prevent negative outcomes and personalization of pharmacological therapy, shifting from reactive to proactive care. Our technology is currently at TRL5 with an MVP that has shown and excellent results in on-going validations. However, before we can offer our solution to cardiologists and primary care clinicians, we must complete key activities in our action plan.
WomenTechEU will help us to better understand pricing and reimbursement strategies for the NIMBLE System in European markets, gain visibility with investors and collaborators, and support and mentoring from being one of the growing numbers of female entrepreneurs. Susana expects that this program supports her in bringing NIMBLE System to the market.